학술논문
Refractory Ulcerative Colitis With Associated Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis Syndrome Successfully Treated With Tofacitinib.
Document Type
Report
Author
Kim BJ; Department of Medicine, University of California, San Francisco, CA.; Thiemann A; Department of Medicine, California Pacific Medical Center, CA.; Dietz B; Department of Rheumatology, University of California, San Francisco, CA.; Beck K; Department of Gastroenterology and Hepatology, University of California, San Francisco, CA.
Source
Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101638398 Publication Model: eCollection Cited Medium: Print ISSN: 2326-3253 (Print) Linking ISSN: 23263253 NLM ISO Abbreviation: ACG Case Rep J Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2326-3253
Abstract
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare inflammatory condition associated with inflammatory bowel disease. Limited data exist on standardized management. We report a case of refractory SAPHO syndrome and ulcerative colitis (UC) treated successfully with tofacitinib. A 54-year-old man with UC presented with an intractable headache. A diagnosis of SAPHO syndrome was made based on the finding of sterile osteitis in the skull base and persistent severe UC. Symptoms, imaging, and endoscopy revealed persistent UC and osteitis despite multiple therapies. Tofacitinib was initiated and clinical remission was achieved. Tofacitinib is an effective treatment of refractory inflammatory bowel disease and SAPHO syndrome.
(© 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
(© 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)